This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aegerion Pharmaceuticals, Inc.
Drug Names(s): BMS-201038, AEGR-733, lomitapide medylate, Lojuxta (EU)
Description: AEGR 733 is a microsomal triglyceride transfer protein (MTP) inhibitor. It was designed to work by a dual mechanism of action: affecting production of both VLDL in the liver and chylomicrons in the intestine, which are responsible for transporting cholesterol and triglycerides. AEGR 733 may also have an effect on LDL cholesterol.
Revenue splits for this drug are BioMedTracker estimates.
In the mid-to-late 1990s, BMS began development of lomitapide. In 2003, BMS donated certain patent rights and other rights related to this product candidate to the University of Pennsylvania.
University of Pennsylvania
In May 2006, Aegerion entered into an exclusive, worldwide patent license with the Trustees of the University of Pennsylvania, or UPenn, for the right to develop and commercialize lomitapide to treat specified patient populations.
Aegerion is obligated under the license agreement to use commercially reasonable efforts to develop, commercialize, market and sell at least one product covered by the licensed patent rights, such as lomitapide. Pursuant to this license agreement, Aegerion paid UPenn a one-time license initiation fee of $56,250. Aegerion will be required to make development milestone payments to UPenn of up to an aggregate of $150,000...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company University of Pennsylvania
Additional information available to subscribers only: